Identification

Name
Mivacurium
Accession Number
DB01226  (APRD01119)
Type
Small Molecule
Groups
Approved
Description

Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission.

Structure
Thumb
Synonyms
  • Mivacurium
Product Ingredients
IngredientUNIICASInChI Key
Mivacurium chloride600ZG213C3106861-44-3WMSYWJSZGVOIJW-ONUALHDOSA-L
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MivacronLiquid2 mgIntravenousAbbvie1994-12-312012-11-03Canada
MivacronSolution2 mg/mLIntravenousAbbvie2015-01-30Not applicableUs
Categories
UNII
77D66S9Q93
CAS number
133814-19-4
Weight
Average: 1029.2608
Monoisotopic: 1028.560955278
Chemical Formula
C58H80N2O14
InChI Key
ILVYCEVXHALBSC-OTBYEXOQSA-N
InChI
InChI=1S/C58H80N2O14/c1-59(25-21-41-35-47(63-3)49(65-5)37-43(41)45(59)29-39-31-51(67-7)57(71-11)52(32-39)68-8)23-17-27-73-55(61)19-15-13-14-16-20-56(62)74-28-18-24-60(2)26-22-42-36-48(64-4)50(66-6)38-44(42)46(60)30-40-33-53(69-9)58(72-12)54(34-40)70-10/h13-14,31-38,45-46H,15-30H2,1-12H3/q+2/b14-13+/t45-,46-,59?,60?/m1/s1
IUPAC Name
(1R)-2-(3-{[(4E)-8-{3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl]propoxy}-8-oxooct-4-enoyl]oxy}propyl)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium
SMILES
COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC

Pharmacology

Indication

For inpatients and outpatients, as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Associated Therapies
Pharmacodynamics

Mivacurium is a short-acting, nondepolarizing skeletal neuromuscular blocking agent which is hydrolyzed by plasma cholinesterase. Mivacurium results in a blockade of neuromuscular transmission by binding competitively with cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine. The neuromuscular block produced by mivacurium is readily antagonized by anticholinesterase agents. The deeper the level of neuromuscular block at reversal, the longer the time required for recovery of neuromuscular function and the greater the dose of anticholinesterase agent required. Because spontaneous recovery after mivacurium is rapid, routine reversal may not always result in a clinical benefit.

Mechanism of action

Mivacurium binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine.

TargetActionsOrganism
ANeuronal acetylcholine receptor subunit alpha-2
antagonist
Human
NMuscarinic acetylcholine receptor M2
antagonist
partial agonist
Human
NMuscarinic acetylcholine receptor M3
antagonist
Human
UCholinesteraseNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

The protein binding of mivacurium has not been determined due to its rapid hydrolysis by plasma cholinesterase.

Metabolism

Extensive and rapid via enzymatic hydrolysis catalyzed by plasma cholinesterase. Biotransformation may be significantly slowed in patients with abnormal or decreased plasma cholinesterase activity, especially individuals with a homozygous atypical cholinesterase gene abnormality.

Route of elimination
Not Available
Half life

The mean elimination half-life ranges from 1.7 to 2.6 minutes in healthy, young adults administered 0.1 to 0.25 mg/kg mivacurium. In 9 patients with end-stage liver disease undergoing liver transplant surgery, plasma clearance was approximately 50% lower than that in 8 control patients with normal hepatic function, while the elimination half-life increased to 4.4 minutes from the 1.8 minute control value.

Clearance
Not Available
Toxicity

Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may decrease the neuromuscular blocking activities of Mivacurium.Experimental
16-BromoepiandrosteroneMivacurium may increase the adverse neuromuscular activities of 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneMivacurium may increase the adverse neuromuscular activities of 19-norandrostenedione.Experimental, Illicit
5-androstenedioneMivacurium may increase the adverse neuromuscular activities of 5-androstenedione.Experimental, Illicit
AcetyldigitoxinMivacurium may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinMivacurium may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
AgmatineAgmatine may increase the neuromuscular blocking activities of Mivacurium.Experimental, Investigational
AlclometasoneMivacurium may increase the adverse neuromuscular activities of Alclometasone.Approved
AldosteroneMivacurium may increase the adverse neuromuscular activities of Aldosterone.Experimental, Investigational
AmbenoniumAmbenonium may decrease the neuromuscular blocking activities of Mivacurium.Approved
AmcinonideMivacurium may increase the adverse neuromuscular activities of Amcinonide.Approved
AmikacinThe therapeutic efficacy of Mivacurium can be increased when used in combination with Amikacin.Approved, Investigational, Vet Approved
AmiodaroneAmiodarone may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
AmlodipineAmlodipine may increase the neuromuscular blocking activities of Mivacurium.Approved
AndrostenedioneMivacurium may increase the adverse neuromuscular activities of Androstenedione.Experimental, Illicit
AnecortaveMivacurium may increase the adverse neuromuscular activities of Anecortave.Investigational
anecortave acetateMivacurium may increase the adverse neuromuscular activities of anecortave acetate.Investigational
ApramycinApramycin may increase the respiratory depressant activities of Mivacurium.Experimental, Vet Approved
AranidipineAranidipine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
ArbekacinArbekacin may increase the respiratory depressant activities of Mivacurium.Approved, Investigational
AtamestaneMivacurium may increase the adverse neuromuscular activities of Atamestane.Investigational
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Mivacurium.Approved, Vet Approved
AzelnidipineAzelnidipine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
AzosemideAzosemide may decrease the neuromuscular blocking activities of Mivacurium.Investigational
BarnidipineBarnidipine may increase the neuromuscular blocking activities of Mivacurium.Approved
Beclomethasone dipropionateThe risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Beclomethasone dipropionate.Approved, Investigational
BekanamycinBekanamycin may increase the respiratory depressant activities of Mivacurium.Experimental
BencyclaneBencyclane may increase the neuromuscular blocking activities of Mivacurium.Experimental
BenidipineBenidipine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Mivacurium.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Mivacurium.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Mivacurium.Approved
BepridilBepridil may increase the neuromuscular blocking activities of Mivacurium.Approved, Withdrawn
BetamethasoneMivacurium may increase the adverse neuromuscular activities of Betamethasone.Approved, Vet Approved
BioallethrinBioallethrin may increase the neuromuscular blocking activities of Mivacurium.Approved, Experimental
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Mivacurium.Approved
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
Botulinum Toxin Type BMivacurium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Mivacurium.Approved
BudesonideThe risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Budesonide.Approved
BumetanideBumetanide may decrease the neuromuscular blocking activities of Mivacurium.Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Mivacurium.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Mivacurium.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Mivacurium.Approved, Investigational
CarboxyamidotriazoleCarboxyamidotriazole may increase the neuromuscular blocking activities of Mivacurium.Investigational
CaroverineCaroverine may increase the neuromuscular blocking activities of Mivacurium.Experimental
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Mivacurium.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Mivacurium.Approved
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may decrease the neuromuscular blocking activities of Mivacurium.Approved
CiclesonideMivacurium may increase the adverse neuromuscular activities of Ciclesonide.Approved, Investigational
CilnidipineCilnidipine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
CinnarizineCinnarizine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Mivacurium.Approved, Investigational
ClevidipineClevidipine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
ClindamycinThe therapeutic efficacy of Mivacurium can be increased when used in combination with Clindamycin.Approved, Vet Approved
ClobetasolMivacurium may increase the adverse neuromuscular activities of Clobetasol.Approved, Investigational
Clobetasol propionateMivacurium may increase the adverse neuromuscular activities of Clobetasol propionate.Approved
ClobetasoneMivacurium may increase the adverse neuromuscular activities of Clobetasone.Approved
ClocortoloneMivacurium may increase the adverse neuromuscular activities of Clocortolone.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Mivacurium.Approved, Illicit
ColistimethateColistimethate may increase the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
Cortexolone 17α-propionateMivacurium may increase the adverse neuromuscular activities of Cortexolone 17α-propionate.Investigational
CorticosteroneMivacurium may increase the adverse neuromuscular activities of Corticosterone.Experimental
Cortisone acetateMivacurium may increase the adverse neuromuscular activities of Cortisone acetate.Approved, Investigational
CoumaphosCoumaphos may decrease the neuromuscular blocking activities of Mivacurium.Vet Approved
CyclandelateCyclandelate may increase the neuromuscular blocking activities of Mivacurium.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mivacurium.Approved
CyclosporineThe therapeutic efficacy of Mivacurium can be increased when used in combination with Cyclosporine.Approved, Investigational, Vet Approved
CymarinMivacurium may increase the arrhythmogenic activities of Cymarin.Experimental
DarodipineDarodipine may increase the neuromuscular blocking activities of Mivacurium.Experimental
DecamethoniumDecamethonium may decrease the neuromuscular blocking activities of Mivacurium.Approved
DeflazacortMivacurium may increase the adverse neuromuscular activities of Deflazacort.Approved, Investigational
DemecariumDemecarium may decrease the neuromuscular blocking activities of Mivacurium.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Mivacurium.Approved
DesfluraneDesflurane may increase the neuromuscular blocking activities of Mivacurium.Approved
DeslanosideMivacurium may increase the arrhythmogenic activities of Deslanoside.Approved
DesonideMivacurium may increase the adverse neuromuscular activities of Desonide.Approved, Investigational
DesoximetasoneMivacurium may increase the adverse neuromuscular activities of Desoximetasone.Approved
Desoxycorticosterone acetateMivacurium may increase the adverse neuromuscular activities of Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateMivacurium may increase the adverse neuromuscular activities of Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Mivacurium is combined with Desvenlafaxine.Approved, Investigational
DexamethasoneThe risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateMivacurium may increase the adverse neuromuscular activities of Dexamethasone isonicotinate.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mivacurium.Approved
DexniguldipineDexniguldipine may increase the neuromuscular blocking activities of Mivacurium.Experimental
DextromethorphanThe risk or severity of adverse effects can be increased when Mivacurium is combined with Dextromethorphan.Approved
DexverapamilDexverapamil may increase the neuromuscular blocking activities of Mivacurium.Experimental
DibekacinDibekacin may increase the respiratory depressant activities of Mivacurium.Experimental
DichlorvosDichlorvos may decrease the neuromuscular blocking activities of Mivacurium.Vet Approved
Diethyl etherDiethyl ether may increase the neuromuscular blocking activities of Mivacurium.Experimental
DiflorasoneMivacurium may increase the adverse neuromuscular activities of Diflorasone.Approved
DifluocortoloneMivacurium may increase the adverse neuromuscular activities of Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateMivacurium may increase the adverse neuromuscular activities of Difluprednate.Approved
DigitoxinMivacurium may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
DigoxinMivacurium may increase the arrhythmogenic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Mivacurium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).Approved
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Mivacurium.Investigational, Vet Approved
DiltiazemDiltiazem may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Mivacurium.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Mivacurium.Approved, Investigational
DipivefrinDipivefrin may decrease the neuromuscular blocking activities of Mivacurium.Approved
DistigmineDistigmine may decrease the neuromuscular blocking activities of Mivacurium.Experimental
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Mivacurium.Approved
DonepezilDonepezil may decrease the neuromuscular blocking activities of Mivacurium.Approved
DotarizineDotarizine may increase the neuromuscular blocking activities of Mivacurium.Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Mivacurium.Approved, Vet Approved
EchothiophateEchothiophate may decrease the neuromuscular blocking activities of Mivacurium.Approved
EdrophoniumEdrophonium may decrease the neuromuscular blocking activities of Mivacurium.Approved
EfonidipineEfonidipine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
EmopamilEmopamil may increase the neuromuscular blocking activities of Mivacurium.Experimental
EnfluraneEnflurane may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational, Vet Approved
EperisoneEperisone may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
EquileninMivacurium may increase the adverse neuromuscular activities of Equilenin.Experimental
EquilinMivacurium may increase the adverse neuromuscular activities of Equilin.Approved
EstroneMivacurium may increase the adverse neuromuscular activities of Estrone.Approved
Estrone sulfateMivacurium may increase the adverse neuromuscular activities of Estrone sulfate.Approved
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Mivacurium.Approved, Investigational
EthanolMivacurium may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthosuximideEthosuximide may increase the neuromuscular blocking activities of Mivacurium.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Mivacurium.Approved
FelodipineFelodipine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
FendilineFendiline may increase the neuromuscular blocking activities of Mivacurium.Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mivacurium.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may decrease the neuromuscular blocking activities of Mivacurium.Vet Approved
Fish oilFish oil may increase the neuromuscular blocking activities of Mivacurium.Approved, Nutraceutical
FluasteroneMivacurium may increase the adverse neuromuscular activities of Fluasterone.Investigational
FludrocortisoneMivacurium may increase the adverse neuromuscular activities of Fludrocortisone.Approved, Investigational
FlumethasoneMivacurium may increase the adverse neuromuscular activities of Flumethasone.Approved, Vet Approved
FlunarizineFlunarizine may increase the neuromuscular blocking activities of Mivacurium.Approved
FlunisolideMivacurium may increase the adverse neuromuscular activities of Flunisolide.Approved, Investigational
Fluocinolone AcetonideMivacurium may increase the adverse neuromuscular activities of Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideMivacurium may increase the adverse neuromuscular activities of Fluocinonide.Approved, Investigational
FluocortoloneMivacurium may increase the adverse neuromuscular activities of Fluocortolone.Approved, Withdrawn
FluorometholoneMivacurium may increase the adverse neuromuscular activities of Fluorometholone.Approved, Investigational
FluoxetineThe risk or severity of adverse effects can be increased when Mivacurium is combined with Fluoxetine.Approved, Vet Approved
FluprednideneMivacurium may increase the adverse neuromuscular activities of Fluprednidene.Approved, Withdrawn
FluprednisoloneMivacurium may increase the adverse neuromuscular activities of Fluprednisolone.Approved
FlurandrenolideMivacurium may increase the adverse neuromuscular activities of Flurandrenolide.Approved
FluspirileneFluspirilene may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
FluticasoneMivacurium may increase the adverse neuromuscular activities of Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateMivacurium may increase the adverse neuromuscular activities of Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Mivacurium.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Mivacurium is combined with Fluvoxamine.Approved, Investigational
FormestaneMivacurium may increase the adverse neuromuscular activities of Formestane.Approved, Investigational, Withdrawn
FosphenytoinFosphenytoin may decrease the neuromuscular blocking activities of Mivacurium.Approved, Investigational
FramycetinFramycetin may increase the respiratory depressant activities of Mivacurium.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
GabapentinGabapentin may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
GalantamineGalantamine may decrease the neuromuscular blocking activities of Mivacurium.Approved
Gallamine TriethiodideGallamine Triethiodide may decrease the neuromuscular blocking activities of Mivacurium.Approved
GallopamilGallopamil may increase the neuromuscular blocking activities of Mivacurium.Investigational
GeneticinGeneticin may increase the respiratory depressant activities of Mivacurium.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Mivacurium.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Mivacurium.Experimental
Ginkgo bilobaGinkgo biloba may decrease the neuromuscular blocking activities of Mivacurium.Approved, Investigational, Nutraceutical
GitoformateMivacurium may increase the arrhythmogenic activities of Gitoformate.Experimental
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Mivacurium.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Mivacurium.Approved, Investigational
HalcinonideMivacurium may increase the adverse neuromuscular activities of Halcinonide.Approved, Investigational, Withdrawn
HalothaneHalothane may increase the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
HE3286Mivacurium may increase the adverse neuromuscular activities of HE3286.Investigational
Huperzine AHuperzine A may decrease the neuromuscular blocking activities of Mivacurium.Approved, Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Mivacurium.Approved, Vet Approved
HydrocodoneMivacurium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Hydrocortisone.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Hydrocortisone butyrate.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may decrease the neuromuscular blocking activities of Mivacurium.Approved, Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Mivacurium.Approved
Hygromycin BHygromycin B may increase the respiratory depressant activities of Mivacurium.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Mivacurium.Approved
IpidacrineIpidacrine may decrease the neuromuscular blocking activities of Mivacurium.Experimental
IpratropiumThe risk or severity of adverse effects can be increased when Mivacurium is combined with Ipratropium.Approved
IsepamicinIsepamicin may increase the respiratory depressant activities of Mivacurium.Experimental
IsofluraneIsoflurane may increase the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
IsoflurophateIsoflurophate may decrease the neuromuscular blocking activities of Mivacurium.Approved, Investigational, Withdrawn
IsradipineIsradipine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
IstaroximeMivacurium may increase the adverse neuromuscular activities of Istaroxime.Investigational
KanamycinKanamycin may increase the respiratory depressant activities of Mivacurium.Approved, Investigational, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mivacurium.Approved
LacidipineLacidipine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Mivacurium.Approved
LamotrigineLamotrigine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
Lanatoside CMivacurium may increase the arrhythmogenic activities of Lanatoside C.Experimental
LercanidipineLercanidipine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
LevetiracetamLevetiracetam may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Mivacurium.Approved
LidoflazineLidoflazine may increase the neuromuscular blocking activities of Mivacurium.Experimental
LincomycinLincomycin may increase the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
Lithium cationLithium may increase the neuromuscular blocking activities of Mivacurium.Experimental
LomerizineLomerizine may increase the neuromuscular blocking activities of Mivacurium.Experimental
LoperamideLoperamide may increase the neuromuscular blocking activities of Mivacurium.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Mivacurium.Approved, Investigational
LorpiprazoleThe therapeutic efficacy of Mivacurium can be increased when used in combination with Lorpiprazole.Approved
LoteprednolMivacurium may increase the adverse neuromuscular activities of Loteprednol.Approved
Magnesium carbonateThe therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium citrate.Approved
Magnesium hydroxideThe therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium hydroxide.Approved, Investigational
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Mivacurium.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Mivacurium.Approved
Magnesium sulfateThe therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium Trisilicate.Approved
MalathionMalathion may decrease the neuromuscular blocking activities of Mivacurium.Approved, Investigational
ManidipineManidipine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
ME-609Mivacurium may increase the adverse neuromuscular activities of ME-609.Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Mivacurium.Approved
MedrysoneMivacurium may increase the adverse neuromuscular activities of Medrysone.Approved
MefloquineMefloquine may decrease the neuromuscular blocking activities of Mivacurium.Approved, Investigational
MelengestrolMivacurium may increase the adverse neuromuscular activities of Melengestrol.Vet Approved
MemantineMemantine may decrease the neuromuscular blocking activities of Mivacurium.Approved, Investigational
MentholMenthol may increase the neuromuscular blocking activities of Mivacurium.Approved
Methanesulfonyl FluorideMethanesulfonyl Fluoride may decrease the neuromuscular blocking activities of Mivacurium.Investigational
MethoxyfluraneMethoxyflurane may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational, Vet Approved
MethsuximideMethsuximide may increase the neuromuscular blocking activities of Mivacurium.Approved
MethyclothiazideMethyclothiazide may decrease the neuromuscular blocking activities of Mivacurium.Approved
MethylprednisoloneThe risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Methylprednisolone.Approved, Vet Approved
MetildigoxinMivacurium may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetoclopramideThe therapeutic efficacy of Mivacurium can be decreased when used in combination with Metoclopramide.Approved, Investigational
MibefradilMibefradil may increase the neuromuscular blocking activities of Mivacurium.Investigational, Withdrawn
MicronomicinMicronomicin may increase the respiratory depressant activities of Mivacurium.Experimental
MinaprineMinaprine may decrease the neuromuscular blocking activities of Mivacurium.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Mivacurium.Approved, Vet Approved
MinocyclineMinocycline may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
MometasoneMivacurium may increase the adverse neuromuscular activities of Mometasone.Approved, Vet Approved
NaftopidilNaftopidil may increase the neuromuscular blocking activities of Mivacurium.Investigational
NCX 1022Mivacurium may increase the adverse neuromuscular activities of NCX 1022.Investigational
NeamineNeamine may increase the respiratory depressant activities of Mivacurium.Experimental
NeomycinThe therapeutic efficacy of Mivacurium can be increased when used in combination with Neomycin.Approved, Vet Approved
NeostigmineNeostigmine may decrease the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Mivacurium.Approved, Investigational
NicardipineNicardipine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
NifedipineNifedipine may increase the neuromuscular blocking activities of Mivacurium.Approved
NiguldipineNiguldipine may increase the neuromuscular blocking activities of Mivacurium.Experimental
NiludipineNiludipine may increase the neuromuscular blocking activities of Mivacurium.Experimental
NilvadipineNilvadipine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
NimesulideNimesulide may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
NisoldipineNisoldipine may increase the neuromuscular blocking activities of Mivacurium.Approved
NitrendipineNitrendipine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
Nitrous oxideNitrous oxide may increase the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
NylidrinNylidrin may increase the neuromuscular blocking activities of Mivacurium.Approved
OleandrinMivacurium may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
Oleoyl-estroneMivacurium may increase the adverse neuromuscular activities of Oleoyl-estrone.Investigational
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Mivacurium.Approved
OtiloniumOtilonium may increase the neuromuscular blocking activities of Mivacurium.Experimental, Investigational
OuabainMivacurium may increase the arrhythmogenic activities of Ouabain.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mivacurium.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Mivacurium.Approved, Investigational, Vet Approved
OxytetracyclineOxytetracycline may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational, Vet Approved
ParamethasoneMivacurium may increase the adverse neuromuscular activities of Paramethasone.Approved
ParaoxonParaoxon may decrease the neuromuscular blocking activities of Mivacurium.Experimental
ParomomycinThe therapeutic efficacy of Mivacurium can be increased when used in combination with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Mivacurium is combined with Paroxetine.Approved, Investigational
PenfluridolPenfluridol may increase the neuromuscular blocking activities of Mivacurium.Experimental
PeruvosideMivacurium may increase the arrhythmogenic activities of Peruvoside.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Mivacurium.Approved, Investigational
PhenytoinPhenytoin may decrease the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
PhysostigminePhysostigmine may decrease the neuromuscular blocking activities of Mivacurium.Approved, Investigational
PinaveriumPinaverium may increase the neuromuscular blocking activities of Mivacurium.Approved
PiretanidePiretanide may decrease the neuromuscular blocking activities of Mivacurium.Approved
PirlimycinPirlimycin may increase the neuromuscular blocking activities of Mivacurium.Vet Approved
PlazomicinPlazomicin may increase the respiratory depressant activities of Mivacurium.Approved, Investigational
Polymyxin B SulfateThe therapeutic efficacy of Mivacurium can be increased when used in combination with Polymyxin B Sulfate.Approved, Vet Approved
Potassium ChlorideThe risk or severity of gastrointestinal ulceration can be increased when Mivacurium is combined with Potassium Chloride.Approved, Withdrawn
PramipexoleMivacurium may increase the sedative activities of Pramipexole.Approved, Investigational
PrasteroneMivacurium may increase the adverse neuromuscular activities of Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateMivacurium may increase the adverse neuromuscular activities of Prasterone sulfate.Investigational
PrednicarbateMivacurium may increase the adverse neuromuscular activities of Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Prednisolone.Approved, Vet Approved
PrednisoneMivacurium may increase the adverse neuromuscular activities of Prednisone.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Mivacurium can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PregnenoloneMivacurium may increase the adverse neuromuscular activities of Pregnenolone.Approved, Experimental, Investigational
PrenylaminePrenylamine may increase the neuromuscular blocking activities of Mivacurium.Withdrawn
ProcainamideProcainamide may increase the neuromuscular blocking activities of Mivacurium.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mivacurium.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Mivacurium.Approved, Investigational
ProscillaridinMivacurium may increase the arrhythmogenic activities of Proscillaridin.Experimental
PseudoephedrineThe risk or severity of adverse effects can be increased when Mivacurium is combined with Pseudoephedrine.Approved
PuromycinPuromycin may increase the respiratory depressant activities of Mivacurium.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Mivacurium is combined with Pyrantel.Approved, Vet Approved
PyridostigminePyridostigmine may decrease the neuromuscular blocking activities of Mivacurium.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Mivacurium.Approved
QuinethazoneQuinethazone may decrease the neuromuscular blocking activities of Mivacurium.Approved
QuinidineQuinidine may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
QuinineQuinine may increase the neuromuscular blocking activities of Mivacurium.Approved
RibostamycinRibostamycin may increase the respiratory depressant activities of Mivacurium.Approved, Investigational
RimexoloneMivacurium may increase the adverse neuromuscular activities of Rimexolone.Approved
RivastigmineRivastigmine may decrease the neuromuscular blocking activities of Mivacurium.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Mivacurium is combined with Rizatriptan.Approved
RopiniroleMivacurium may increase the sedative activities of Ropinirole.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mivacurium.Approved, Investigational
SeletracetamSeletracetam may increase the neuromuscular blocking activities of Mivacurium.Investigational
SevofluraneSevoflurane may increase the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
SisomicinSisomicin may increase the respiratory depressant activities of Mivacurium.Investigational
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Mivacurium.Approved
SpironolactoneSpironolactone may increase the neuromuscular blocking activities of Mivacurium.Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Mivacurium.Approved, Vet Approved
SumatriptanThe risk or severity of adverse effects can be increased when Mivacurium is combined with Sumatriptan.Approved, Investigational
TacrineTacrine may decrease the neuromuscular blocking activities of Mivacurium.Investigational, Withdrawn
TerodilineTerodiline may increase the neuromuscular blocking activities of Mivacurium.Experimental
TetracyclineThe therapeutic efficacy of Mivacurium can be increased when used in combination with Tetracycline.Approved, Vet Approved
TetrahydropalmatineTetrahydropalmatine may increase the neuromuscular blocking activities of Mivacurium.Investigational
TetrandrineTetrandrine may increase the neuromuscular blocking activities of Mivacurium.Experimental
TixocortolMivacurium may increase the adverse neuromuscular activities of Tixocortol.Approved, Withdrawn
TobramycinTobramycin may increase the respiratory depressant activities of Mivacurium.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
TopiramateThe risk or severity of hyperthermia and oligohydrosis can be increased when Mivacurium is combined with Topiramate.Approved
TorasemideTorasemide may decrease the neuromuscular blocking activities of Mivacurium.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Mivacurium.Approved, Investigational
TranilastTranilast may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
TriamcinoloneMivacurium may increase the adverse neuromuscular activities of Triamcinolone.Approved, Vet Approved
TrichlorfonTrichlorfon may decrease the neuromuscular blocking activities of Mivacurium.Vet Approved
TrichlormethiazideTrichlormethiazide may decrease the neuromuscular blocking activities of Mivacurium.Approved, Vet Approved
TrichloroethyleneTrichloroethylene may increase the neuromuscular blocking activities of Mivacurium.Approved
TrimebutineTrimebutine may increase the neuromuscular blocking activities of Mivacurium.Approved
TrimethadioneTrimethadione may increase the neuromuscular blocking activities of Mivacurium.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Mivacurium.Approved
TubocurarineTubocurarine may decrease the neuromuscular blocking activities of Mivacurium.Approved
TyrothricinTyrothricin may decrease the neuromuscular blocking activities of Mivacurium.Approved
UlobetasolMivacurium may increase the adverse neuromuscular activities of Ulobetasol.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Mivacurium.Approved, Investigational
VancomycinThe therapeutic efficacy of Mivacurium can be increased when used in combination with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Mivacurium.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Mivacurium is combined with Venlafaxine.Approved
VerapamilVerapamil may increase the neuromuscular blocking activities of Mivacurium.Approved
VinpocetineVinpocetine may increase the neuromuscular blocking activities of Mivacurium.Investigational
WIN 55212-2The risk or severity of Tachycardia and drowsiness can be increased when Mivacurium is combined with WIN 55212-2.Experimental
XenonXenon may increase the neuromuscular blocking activities of Mivacurium.Experimental
ZiconotideZiconotide may increase the neuromuscular blocking activities of Mivacurium.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Mivacurium is combined with Zolmitriptan.Approved, Investigational
ZolpidemMivacurium may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideZonisamide may increase the neuromuscular blocking activities of Mivacurium.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Maurizio Francesco Velati, Andrea Busca, Cristina Manfrotto, Marco Nicolini, Claudio Gianluca Pozzoli, "Process for the preparation of mivacurium chloride." U.S. Patent US20070293534, issued December 20, 2007.

US20070293534
General References
Not Available
External Links
Human Metabolome Database
HMDB0015357
KEGG Compound
C07550
PubChem Compound
5281042
PubChem Substance
46505071
ChemSpider
4444509
ChEBI
6958
ChEMBL
CHEMBL1182833
Therapeutic Targets Database
DAP000716
PharmGKB
PA450528
RxList
RxList Drug Page
Wikipedia
Mivacurium
ATC Codes
M03AC10 — Mivacurium chloride
FDA label
Download (1.5 MB)
MSDS
Download (25.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentMuscle Relaxation / Sex1
2RecruitingTreatmentLiver Dysfunction1
4CompletedPreventionKidney Diseases / Prostate Hypertrophy1
4CompletedTreatmentEfficacy and Safety of Mivacurium Chloride for Pediatric Patients1
4CompletedTreatmentIntubations / Newborns / Preterms1
Not AvailableCompletedNot AvailableNeuromuscular Blockade1
Not AvailableCompletedTreatmentIntubating Conditions / Performance With Respiratory Exercise Device / Postoperative Myalgia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
LiquidIntravenous2 mg
SolutionIntravenous2 mg/mL
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.26e-05 mg/mLALOGPS
logP3.8ALOGPS
logP-0.76ChemAxon
logS-7.5ALOGPS
pKa (Strongest Acidic)18.59ChemAxon
pKa (Strongest Basic)-4.1ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area144.9 Å2ChemAxon
Rotatable Bond Count30ChemAxon
Refractivity308.74 m3·mol-1ChemAxon
Polarizability116.68 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9832
Blood Brain Barrier+0.9465
Caco-2 permeable+0.629
P-glycoprotein substrateSubstrate0.8476
P-glycoprotein inhibitor INon-inhibitor0.5119
P-glycoprotein inhibitor IIInhibitor0.7645
Renal organic cation transporterNon-inhibitor0.5515
CYP450 2C9 substrateNon-substrate0.8376
CYP450 2D6 substrateNon-substrate0.7529
CYP450 3A4 substrateSubstrate0.6975
CYP450 1A2 substrateNon-inhibitor0.8986
CYP450 2C9 inhibitorNon-inhibitor0.9583
CYP450 2D6 inhibitorNon-inhibitor0.8914
CYP450 2C19 inhibitorNon-inhibitor0.9348
CYP450 3A4 inhibitorNon-inhibitor0.8426
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.919
Ames testNon AMES toxic0.7046
CarcinogenicityNon-carcinogens0.9137
BiodegradationNot ready biodegradable0.876
Rat acute toxicity2.6607 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8134
hERG inhibition (predictor II)Non-inhibitor0.6401
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzylisoquinolines. These are organic compounds containing an isoquinoline to which a benzyl group is attached.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Isoquinolines and derivatives
Sub Class
Benzylisoquinolines
Direct Parent
Benzylisoquinolines
Alternative Parents
Tetrahydroisoquinolines / Phenoxy compounds / Anisoles / Methoxybenzenes / Alkyl aryl ethers / Aralkylamines / Fatty acid esters / Dicarboxylic acids and derivatives / Tetraalkylammonium salts / Carboxylic acid esters
show 7 more
Substituents
Benzylisoquinoline / Tetrahydroisoquinoline / Phenoxy compound / Anisole / Phenol ether / Methoxybenzene / Alkyl aryl ether / Fatty acid ester / Aralkylamine / Monocyclic benzene moiety
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
isoquinolines (CHEBI:6958)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Drug binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA2
Uniprot ID
Q15822
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-2
Molecular Weight
59764.82 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Ihmsen H, Schmidt J, Schwilden H, Schmitt HJ, Muenster T: Influence of disease progression on the neuromuscular blocking effect of mivacurium in children and adolescents with Duchenne muscular dystrophy. Anesthesiology. 2009 May;110(5):1016-9. doi: 10.1097/ALN.0b013e31819daf31. [PubMed:19352159]
  4. Jonsson Fagerlund M, Dabrowski M, Eriksson LI: Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. doi: 10.1097/ALN.0b013e31819fade3. [PubMed:19417616]
  5. Jonsson M, Gurley D, Dabrowski M, Larsson O, Johnson EC, Eriksson LI: Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade. Anesthesiology. 2006 Sep;105(3):521-33. [PubMed:16931985]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
Partial agonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Habre W, Adamicza A, Lele E, Novak T, Sly PD, Petak F: The involvement of histaminic and muscarinic receptors in the bronchoconstriction induced by myorelaxant administration in sensitized rabbits. Anesth Analg. 2008 Dec;107(6):1899-906. doi: 10.1213/ane.0b013e318186587c. [PubMed:19020136]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Kao YJ, Le ND: The reversal of profound mivacurium-induced neuromuscular blockade. Can J Anaesth. 1996 Nov;43(11):1128-33. [PubMed:8922768]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 07:52